BridgeMD
New treatment option for Charcot-Marie-Tooth Disease Type 1A
Official title Clinical Trial Evaluating the Impact of an Intensive Rehabilitation Program Combined With Tendon Vibratory Stimulation on Functional Balance in Individuals With Charcot-Marie-Tooth Disease Type 1A
ClinicalTrials.gov ID: NCT07726043
What this study is testing
- What it's testing
- Charcot-Marie-Tooth (CMT) disease is caused by a genetic abnormality involving the PMP22 gene, resulting in demyelination of the peripheral nerves. Demyelination leads to sensorimotor impairment and causes progressive muscle weakness and tendon contractures, initially affecting the lower limbs.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Individuals with genetically confirmed Charcot-Marie-Tooth disease type 1A (CMT1A), characterized by PMP22 gene duplication on chromosome 17...
- Age between 18 and 65 years.
- Overall Neuropathy Limitations Scale (ONLS) score between 2 and 3/7 for the lower limbs.
- Affiliation with a social security/health insurance system.
- Written informed consent voluntarily provided after receiving information regarding the study objectives, procedures, and potential risks.
You likely can't join if
- Comorbidities causing peripheral neuropathy (e.g., diabetes, renal failure, medication-induced neuropathy).
- Balance or gait disorders due to another cause.
- Individuals without a permanent residence.
- Individuals deprived of liberty by judicial or administrative decision or under legal guardianship.
- Individuals unable to understand the study objectives and procedures or unable to provide informed consent.
- Individuals unable to complete all study procedures.
See the full eligibility criteria
- Individuals with genetically confirmed Charcot-Marie-Tooth disease type 1A (CMT1A), characterized by PMP22 gene duplication on chromosome 17 (17p11.2).
- Age between 18 and 65 years.
- Overall Neuropathy Limitations Scale (ONLS) score between 2 and 3/7 for the lower limbs.
- Affiliation with a social security/health insurance system.
- Written informed consent voluntarily provided after receiving information regarding the study objectives, procedures, and potential risks.
- Comorbidities causing peripheral neuropathy (e.g., diabetes, renal failure, medication-induced neuropathy).
- Balance or gait disorders due to another cause.
- Individuals without a permanent residence.
- Individuals deprived of liberty by judicial or administrative decision or under legal guardianship.
- Individuals unable to understand the study objectives and procedures or unable to provide informed consent.
- Individuals unable to complete all study procedures.
- Previous use of the Vibramoov device.
- Pregnant women or women planning to become pregnant during the study period.
- Concurrent participation in another research study.
The study team makes the final eligibility decision.
Where it's taking place
- Marseille, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Marseille, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.